Cyclopamine was subsequently demonstrated to bind to and inhibit SMO [26], and based on these early findings, several additional SMO antagonists have been developed and tested clinically, including vismodegib and sonidegib, which are approved for advanced BCC, and glasdegib for AML. The gene discussed is SMO; the disease is acute myeloid leukemia.